Syncom Formulations (India) Limited (NSE:SYNCOMF)
13.99
+0.01 (0.07%)
Jun 19, 2026, 3:29 PM IST
NSE:SYNCOMF Revenue
In the fiscal year ending March 31, 2026, Syncom Formulations (India) had annual revenue of 4.89B INR with 5.20% growth. Syncom Formulations (India) had revenue of 1.35B in the quarter ending March 31, 2026, a decrease of -9.04%.
Revenue
4.89B
Revenue Growth
+5.20%
P/S Ratio
2.69
Revenue / Employee
6.57M
Employees
744
Market Cap
13.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.89B | 241.59M | 5.20% |
| Mar 31, 2025 | 4.65B | 2.02B | 76.55% |
| Mar 31, 2024 | 2.63B | 391.33M | 17.45% |
| Mar 31, 2023 | 2.24B | 45.91M | 2.09% |
| Mar 31, 2022 | 2.20B | -251.42M | -10.27% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Solara Active Pharma Sciences | 13.69B |
| Windlas Biotech | 9.04B |
| RPG Life Sciences | 7.08B |
| Ind-Swift Laboratories | 6.41B |
| Sigachi Industries | 4.86B |
| Beta Drugs | 3.85B |
| Jagsonpal Pharmaceuticals | 2.87B |